-
1.发明授权
公开(公告)号：KR101308940B1
公开(公告)日：2013-09-23
申请号：KR1020100043007
申请日：2010-05-07
Applicant: 서울대학교산학협력단
IPC: A61K39/395 , A61P35/00
Abstract: 본 발명은 프로테아좀 저해제 및 Gα12 및/또는 Gα13 단백질 기능의 억제 또는 하향 조절제를 함께 사용한, 종양의 성장억제, 경감 또는 치료와 관련된 것이다. 또한 본 발명은 프로테아좀 저해제 및 Gα12 및/또는 Gα13 단백질 기능의 억제 또는 하향 조절제를 함께 사용한, 프로테아좀 저해제에 대한 저항성 종양의 성장억제, 경감 또는 치료와 관련된 것이다.
-
公开(公告)号：KR101269208B1
公开(公告)日：2013-05-30
申请号：KR1020100051458
申请日：2010-05-31
Applicant: 서울대학교산학협력단
Abstract: 본발명은사우치논또는사우치논이풍부한삼백초추출분획물을유효성분으로포함하는조성물에관한것으로, 본발명의조성물은인슐린저항성을개선하여간세포에서당생성을억제하고근육세포및 지방세포의당이용율을높이며, 혈당감소및 체중감소효과가있어, 인슐린저항성, 인슐린저항성관련질병, 인슐린저항성증후군의예방, 개선또는치료용조성물및 이를포함하는의약또는건강기능식품으로유용하게이용할수 있다.
-
公开(公告)号：KR1020110131821A
公开(公告)日：2011-12-07
申请号：KR1020100051458
申请日：2010-05-31
Applicant: 서울대학교산학협력단
CPC classification number: A61K36/78 , A23V2200/322 , A23V2200/326 , A23V2200/3262 , A23V2200/328 , A61K2236/33 , A61K2236/39 , Y10S514/824 , Y10S514/866 , Y10S514/909
Abstract: PURPOSE: A composition containing Saururus chinensis BAILL. or sauchinone is provided to suppress glycosylation and to reduce blood glucose and body weight. CONSTITUTION: A pharmaceutical composition for preventing or treating insulin resistance, insulin resistance-associated disease or insulin resistance syndrome contains 0.01-99.9 % of sauchinone or Saururus chinensis BAILL. extract fraction as an active ingredient. A method for preparing the Saururus chinensis BAILL. extract fraction comprises: a step of extracting Saururus chinensis BAILL. with non-polar solvent and removing the non-polar ingredients; a step of isolating with a less polar solvent; and a step of fractioning using n-hexane-ethyl acetate. The composition is manufactured in the form of powder, granule, tablet, capsule, suspension, emulsion, syrup, suppository, and sterilized injection solution.
Abstract translation: 目的：含有Saururus chinensis BAILL的组合物。 或提供橙酮以抑制糖基化并降低血糖和体重。 构成：用于预防或治疗胰岛素抵抗，胰岛素抵抗相关疾病或胰岛素抵抗综合症的药物组合物含有0.01-99.9％的sauchinone或Saururus chinensis BAILL。 提取物级分作为活性成分。 一种制备Saururus chinensis BAILL的方法。 提取物组分包括：提取中华白菜BAILL的步骤。 用非极性溶剂除去非极性成分; 用极性较小的溶剂分离的步骤; 和使用正己烷 - 乙酸乙酯分馏的步骤。 该组合物以粉末，颗粒，片剂，胶囊，悬浮液，乳剂，糖浆，栓剂和灭菌注射液的形式制备。
-
4.发明公开
公开(公告)号：KR1020110123491A
公开(公告)日：2011-11-15
申请号：KR1020100043007
申请日：2010-05-07
Applicant: 서울대학교산학협력단
IPC: A61K39/395 , A61P35/00
CPC classification number: A61K38/55 , A61K39/395 , Y10S514/885
Abstract: PURPOSE: A composition containing a proteasome inhibitor and a down-regulator of G alpha12 and/or G alpha13 function is provided. CONSTITUTION: A pharmaceutical composition for suppressing tumor contains inhibitor of G alpha12 or G alpha 13, proteasome inhibitor, and pharmaceutically acceptable carrier. The function inhibitor and proteasome inhibitor are administered at once or separately. The inhibitor of G alpha12 function is a minigene encoding G alpha12 C-terminal, an antisense oligonucleotide to G alpha 12 gene, an antipeptide to G alpha12, a G alpha12 target siRNA, an antibody to G alpha12 receptor, or antagonist to the receptor.
Abstract translation: 目的：提供含有蛋白酶体抑制剂和Gα12和/或Gα13功能下调的组合物。 构成：用于抑制肿瘤的药物组合物含有Gα12或Gα13抑制剂，蛋白酶体抑制剂和药学上可接受的载体。 功能抑制剂和蛋白酶体抑制剂一次或分开施用。 Gα12功能的抑制剂是编码Gα12C-末端的小基因，Gα12基因的反义寡核苷酸，Gα12的抗肽，Gα12靶siRNA，对Gα12受体的抗体或受体的拮抗剂。
-
-
-
Search Results
4
records
(took 0.018 seconds)
